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Abstract: In order to characterize the molecular events in the carcinogenesis of esophageal 
cancer  and  to  identify  biomarkers  for  the  early  detection  of  the  disease,  matched 
precancerous  and  cancerous  tissues  resected  from  34  esophageal  cancer  patients  in 
Chongqing of southern China were compared for the extent of loss of heterozygosity (LOH). 
Sixteen microsatellite markers on nine chromosome regions were used for the PCR-based 
LOH analysis. The overall frequency of LOH at the 16 microsatellite loci was significantly 
increased as the pathological status of the resection specimens changed from low-grade 
dysplasia  (LGD)  to  high-grade  dysplasia  (HGD)  and  squamous  cell  carcinoma  (SCC)  
(P  <  0.001),  indicating  that  tumorigenesis  of  the  esophageal  squamous  epithelia  is  a 
progressive  process  involving  accumulative  changes  of  LOH.  A  total  of  eight  markers 
showed  LOH  in  the  LGD  samples,  suggesting  that  these  loci  may  be  involved  in  the 
early-stage tumorigenesis of esophageal squamous cell carcinoma (ESCC) and that LOH 
analysis at these loci may help improve the early detection of this disease. In addition, 
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heterozygosity was regained at four loci in the SCC samples of four patients compared with 
the HGD samples, suggesting the possibility of genetic heterogeneity in the tumorigenesis of 
esophageal cancer. 
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1. Introduction 
Esophageal squamous cell carcinoma (ESCC) is a common type of malignant cancer in China,  
with 5-year survival rate less than 15%. Although radical esophagectomy is still the primary treatment 
for  esophageal  cancer,  it  is  quite  difficult  to treat  patients  with  distant  or  lymph-node  metastasis. 
Therefore, identification of biomarkers that can improve the early diagnosis of esophageal cancer or 
precursor lesions will significantly reduce mortality in esophageal cancer patients. Similar to other solid 
tumors, chromosome loss is a common molecular defect in esophageal cancer. A study of chromosome 
loss  in  dysplasia  and  early-stage  esophageal  cancer  will  be  helpful  in  the  discovery  of  major 
tumor-associated genes and will lead to the understanding of the tumorigenesis of esophageal cancer. 
They will also be potential biomarkers for early detection of esophageal cancer. Although extensive 
genomic instability has been found in patients with esophageal cancer, the molecular alterations that are 
closely related to the different stages of tumorigenesis have not been fully understood. In order to further 
clarify the molecular alterations during the early-stage tumorigenesis of ESCC, and to identify potential 
biomarkers for early detection of the disease, we analyzed allelic losses at total of 16 microsatellite loci 
selected from chromosome regions 3p, 4p, 5q, 8p, 9p, 9q, 11p, 13q, and 17p in matched squamous 
dysplasia and squamous cancer tissues resected from 34 esophageal cancer patients in Chongqing of 
southern China. 
2. Results  
The overall frequencies of loss of heterozygosity (LOH) at the 16 microsatellite loci significantly 
increased as the pathological status of the resection samples changed (from low-grade dysplasia (LGD) 
to high-grade dysplasia (HGD) and to squamous cell carcinoma (SCC)) (Table 1). The overall frequency 
of LOH in the LGD samples (9.8%) was significantly lower than that in the HGD (48.6%) and SCC 
(58.5%) samples (P < 0.001). Although the LOH frequency at each locus showed an increasing trend 
with increasing disease severity, the difference was not statistically significant. Eight loci (D3S1597, 
D3S2452,  D3S1285,  D4S174,  D5S2501,  D9S125,  D13S153,  and  D17S786)  showed  LOH  in  the 
informative LGD samples, and another eight loci were found to present LOH in the informative HGD 
specimens. All 16 loci were found to have LOH in the SCC samples. Furthermore, by comparing the 
occurrence of LOH in samples with different pathological statuses from the same patient, we found a 
regain of heterozygosity at loci D3S2452, D4S174, D9S125 and D17S261, in the SCC samples of  
four  patients,  respectively  comparing  to  the  HGD  specimens  which  showed  LOH  at  the 
corresponding loci. Int. J. Mol. Sci. 2011, 12  7403 
 
Table 1. The frequencies of loss of heterozygosity (LOH) at 16 microsatellite loci in the 
squamous dysplastic tissues and esophageal squamous cell carcinoma (ESCC) tissues. 
Marker  Location  LGD 
a sample (%)  HGD 
a sample (%)  SCC 
a sample (%) 
3S1597  3p25  4/21 (19)  12/22 (54.5)  18/22 (81.8) 
D3S2452  3p21-p14  7/25 (28)  20/25 (80)  18/25 (72) 
D3S1285  3p14  3/19 (15.8)  14/21 (66.7)  16/21 (76.2) 
D4S174  4p14-p13  2/27 (7.4)  7/27 (25.9)  12/27 (44.4) 
D5S409  5q14-q15  0/16 (0)  7/16 (43.7)  8/16 (50) 
D5S2501  5q21-q23.3  1/13 (7.7)  7/13 (53.8)  7/13 (53.8) 
D8S261  8p22-p21.3  0/18 (0)  5/18 (27.8)  6/18 (33.3) 
D9S157  9p23-p22  0/23 (0)  16/23 (69.5)  15/23 (65.2) 
D9S111  9q12-q21.1  0/25 (0)  9/25 (36)  15/25 (60) 
D9S125  9q34-q34  9/27 (33.3)  21/27 (77.8)  23/27 (85.2) 
D11S1338  11p15.5  0/29 (0)  10/29 (34.5)  11/29 (37.9) 
D13S175  13q13  0/22 (0)  10/23 (43.5)  12/23 (52.2) 
D13S153  13q14.2  4/24 (16.7)  10/24 (41.7)  13/24 (54.2) 
D13S173  13q32-q34  0/24 (0)  5/24 (20.8)  11/24 (45.8) 
D17S786  17p13.1  5/23 (21.7)  13/23 (56.5)  16/23 (69.5) 
D17S261  17p11.2  0/22 (0)  10/22 (45.4)  11/22 (50) 
Total 
b    35/358 (9.8)  176/362 (48.6)  212/362 (58.5) 
a LGD: low-grade dysplasia, including mild and medium dysplasia (in this study); HGD: high-grade 
dysplasia, i.e., severe dysplasia; SCC: squamous cell carcinoma; 
b If P < 0.001, then the difference is 
statistically significant. 
3. Discussion 
A total of 16 highly polymorphic microsatellite markers from nine chromosome regions with a  
high  frequency  of  allelic  loss  in  esophageal  cancer  were  selected.  Surgically  resected  squamous 
dysplasia and SCC samples from 34 esophageal cancer patients were subjected to LOH analysis at these 
loci. The results showed that the overall frequencies of LOH at the 16 microsatellite loci significantly 
increased as the pathological status of the resection specimens deteriorated (i.e., from LGD to HGD and 
to SCC). These results indicated that tumorigenesis of esophageal squamous epithelia is a progressive 
process involving a series of molecular alterations. As the alterations accumulate to a certain degree, the 
cell morphology and behavior undergoes a radical change, leading to malignancy [1]. This finding  
was consistent with the studies for other tumor types, such as prostate cancer, colon cancer, and breast 
cancer [2–5]. Moreover, the results were also in accordance with those of a previous study showing that 
increasing grades of dysplasia were associated with an increased risk of developing ESCC [6].  
Of 16 loci, we found eight loci to show LOH in low-grade dysplasia, indicating that LOH at these 
eight loci may be involved in the early-stage tumorigenesis of ESCC, and that these specific loci could 
be used as markers for screening of esophageal cancer. At present, some tumor-associated genes have 
been identified near these loci, such as FHIT (3p), RASSF1A (3p), APC (5q), ANXI (9q), DEC1 (9q), 
RB1 (13q), BRCA2 (13q), ING1 (13q), and TP53 (17p). The expression of ANXI in chromosome 9q has 
been reported to be closely related to the tumor progression in patients with breast cancer and possibly 
plays an important role in the early stage of tumorigenesis [7]. Recently, study of this gene in esophageal Int. J. Mol. Sci. 2011, 12  7404 
 
cancer showed that its expression at protein level in cancer tissues is significantly lower than that in 
normal  tissues  [8].  Another  candidate  gene  DEC1  at  chromosome  9q  has  been  reported  to  be 
down-regulated  in  esophageal  cancer,  and  transfection  of  the  cDNA  of  DEC1  could  inhibit  the 
proliferation of some cancer cells, suggesting that it may participate in the development of esophageal 
cancer [9]. The chromosome 13q region has a high frequency of allelic loss in esophageal cancer. 
However, the identified candidate genes within this region, such as RB1, BRCA2, and ING1, seldom 
show mutations in esophageal cancer, implying that other unknown tumor-suppressor genes within this 
region might participate in the tumorigenesis of this cancer [10]. The chromosome 17p region involving 
the P53 locus also shows a high frequency of allelic loss in esophageal cancer. Studies of the P53 gene in 
esophageal cancer have shown that LOH and mutations are the leading causes of its inactivation, which 
is in accordance with the “two-hit” model of tumorigenesis and indicates that P53 is a major tumor 
suppressor in esophageal cancer [11]. 
In addition, eight other loci were found to show LOH in the HGD samples, indicating that LOH at  
these loci may be involved in the late stages of tumorigenesis (such as invasion and metastasis) in 
esophageal cancer.  
This study also compared the occurrence of LOH in samples of different pathological statuses from 
the same patient. Interestingly, in four patients, LOH was found at some loci in the HGD samples, 
whereas  heterozygosity  was  regained  at  the  same  loci  in  matched  SCC  samples.  The  regain  of 
heterozygosity at some loci in tumor tissues indicated that the tumorigenesis of esophageal cancer may 
show genetic heterogeneity, i.e., the HGD and SCC samples of the same patient may have been derived 
from different tumor-cell clones. Cells with different molecular defects may have distinct tumorigenesis 
processes, leading to different tumor-cell clones. A similar result has been found in adenocarcinoma of 
the esophagus; the molecular defects found in the severe dysplastic lesions were not detected in the 
invasive adenocarcinoma lesions of the same patient [12]. A study of patients with oral squamous cancer 
has also shown that most of the molecular alterations found in the precursor lesions were not revealed in 
the matched tumor tissues [13]. Similar observations have been reported in studies of other cancers such 
as breast cancer and prostate cancer [14,15].  
Finally, it is worth mentioning that in some LGD samples of our subjects, there were already multiple 
loci to exhibit allelic loss, indicating that the earliest molecular event in esophageal cancer may occur in 
the histologically normal squamous epithelia. In a recent study on esophageal cancer, the researcher 
found that 19% of the histologically normal epithelia within the abnormal mucosal region (unstained 
with  iodine)  already  showed  LOH  alterations,  suggesting  that  the  histologically  normal  epithelia 
adjacent to the tumor tissues may have early-stage LOH alterations, which might be necessary for the 
tumorigenesis  of  esophageal  cancer  [16].  Although  at  present,  histological  examination  is  still  an 
effective method for the early detection of cancer, molecular tests such as LOH analysis of certain 
specific loci at the early stage can be a promising and more rational strategy for the early diagnosis or 
prediction of esophageal cancer. Int. J. Mol. Sci. 2011, 12  7405 
 
4. Experimental Section 
4.1. Sample Collection  
The resection specimens from a total of 34 esophageal cancer patients were obtained from the 
Department of Thoracic Surgery, South-west Hospital, Chongqing, China. The patients included 23 men 
and 11 women with an average age of 58.6 years (44–74 years). All the patients were newly diagnosed 
with esophageal cancer, did not have a history of any other malignant cancer, and had not undergone any 
radiotherapy or chemotherapy. The patients were all Han Chinese who had lived in Chongqing for more 
than 20 years and did not have any direct kinship with each other. The resected samples were placed in 
liquid nitrogen immediately after the surgical removal and were preserved at −80 °C before use. Besides 
the cancerous foci, surrounding tissues were also collected from the 34 patients. The tissue samples were 
pathologically diagnosed with mild, medium, and severe dysplasia and SCC [17]. This study classified 
mild and medium dysplasia as low-grade dysplasia (LGD) and severe dysplasia as high-grade dysplasia 
(HGD). In addition, peripheral blood samples were collected before surgery. Informed consent had been 
obtained  from  all  the  study  subjects  in  accordance  with  the  standards  established  by  the  local 
institutional review boards. 
4.2. Tissue Cell Acquisition by Using Microdissection 
The  frozen  sections  of  squamous-cancer  tissue  and  dysplastic  tissue  (5  µm)  were  stained  with 
hematoxylin and eosin (HE) and subjected to microdissection under a 40× dissecting microscope to 
ensure that the proportion of tumor cells and dysplastic cells was higher than 80%, which would 
significantly reduce the rates of false positive or negative results during LOH analysis.  
4.3. Extraction of Genomic DNA 
Genomic DNA was extracted from the patients’ blood samples and tissues by using the DNeasy 
Blood and Tissue Kit (QIAGEN).  
4.4. Loss of Heterozygosity (LOH) Analysis 
A total of 16 microsatellite loci were chosen from the 3p, 4p, 5q, 8p, 9p, 9q, 11p, 13q, and 17p 
chromosome regions with a high frequency of allelic loss in esophageal cancer. A majority of these 
markers were dinucleotides and their maximum heterozygosity was more than 70%. Also the locus was 
confirmed as informative in our subjects. The resected samples and paired blood samples from the  
34 esophageal cancer patients were analyzed for LOH at the 16 loci. Information about these markers 
and primer sequences is available on the Genome Database [18] and the NCBI genome database [19]. 
The primers were obtained as labeled primers with fluorescent dye at the 5-terminus (MWG Biotech, 
Ebersberg, Germany). 
LOH analysis was performed as described in our previous paper [20]. In brief, the 5 µL volume of 
microsatellite DNA amplification included 40 ng of DNA template, 1× Buffer, 200 µM dNTPs, 250 nM 
microsatellite primer, 2.5 mM MgCl2, and 0.25 U of Taq DNA polymerase. The PCR conditions were as 
follows: predenaturation at 94 °C for 3 min, followed by 30 cycles of 94 °C for 30 s→55~60 °C for  Int. J. Mol. Sci. 2011, 12  7406 
 
30 s→72 °C for 1 min, and a final elongation step at 72 °C for 4 min. PCR products were loaded on a 
fluorescent sequencer gel (ABI PRISM 377). The images were captured, converted, and analyzed by 
using the GeneScan software, and the size of each allele fragment was automatically calculated.  
If the peripheral blood DNA of a patient showed heterozygosity at a certain locus, then the locus  
was marked as informative. The tissue sample of the patient was considered to show LOH if the DNA 
from the sample showed homozygosity at the informative locus or if the fluorescence intensity of one of 
the 2 alleles was less than 30% of that in the blood DNA of the patient (Figure 1). The frequency of LOH 
at each locus was defined as the total number of tissue samples with LOH at this locus / the total number 
of informative samples. 
Figure  1.  The  X-coordinate  represents  the  size  of  the  fragment,  and  the  Y-coordinate 
represents the fluorescence intensity. (A,B) Allelotyping results of the D3S2452 locus from 
the  peripheral-blood  samples  and  cancer-tissue  samples  of  a  patient.  DNA  from  the 
peripheral-blood sample shows heterozygosity at the D3S2452 locus with fragments of  
2 sizes—149 bp and 153 bp, whereas DNA from the tumor tissue only shows a single 
fragment—149  bp  (arrowhead  indicates  the  loss  of  a  153-bp  fragment).  These  results 
indicate that LOH occurred at the D3S2452 locus in the cancer tissue. (C,D) Allelotyping 
results of the D4S174 locus from the peripheral blood and LGD-tissue samples of a patient. 
Both the peripheral blood and LGD samples comprise segments of 2 sizes—157 bp and  
169 bp—at the D4S174 locus; the fluorescence intensity at the 169 bp segment (arrowhead) 
in the LGD sample was reduced by at least 30% of that in the peripheral-blood sample. The 
results highlight the presence of  LOH  at the D4S174 locus in the  LGD sample. SCC: 
squamous cell carcinoma; LGD: low-grade dysplasia, including mild and medium dysplasia 
(in this study). 
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Figure 1. Cont. 
 
(C) Blood DNA 
 
(D) LGD DNA (the arrow changed) 
4.5. Statistical Analysis 
The LOH frequencies at each locus between the different groups were compared by using the χ
2 test, 
and a P value less than 0.05 was considered statistically significant. 
5. Conclusions 
The tumorigenesis of ESCC is a progressive process involving the accumulative alterations of LOH. 
The identification of eight loci already showing allelic loss in LGD suggests that they may be associated 
with the early-stage tumorigenesis of esophageal cancer, and could be used as molecular markers for 
early detection or prediction of this cancer. 
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